Introduction
Detection of silent brain infarcts (SBI) or other cerebrovascular lesions has become more frequent with the improvement and increasing availability of neuroimaging techniques, such as CT and MRI. A population-based longitudinal study has demonstrated that the presence of SBI on MRI is an infor stroke and vascular dementia (7) (8) (9) (10) (11) (12) (13) , but it remains unclear whether the treatment of hypertension can prevent the progression of SBI. In fact, several authors have claimed that an excessive fall in blood pressure (3, 14) or nocturnal blood pressure (15, 16) may actually increase the risk of SBI and dementia. On the other hand, there is experimental and clinical evidence to suggest that blocking the renin-angiotensinaldosterone system (RAS) may have a protective effect against stroke that goes beyond its influence on the blood pressure (17) (18) (19) (20) (21) (22) .
Recently, the Perindopril Protection against Recurrent Stroke Study (PROGRESS) has demonstrated that a blood pressure lowering regimen based on the angiotensin-converting enzyme (ACE) inhibitor, perindopril, reduced the risk of stroke (23) , cardiac events (24) and stroke-related dementia (25) . Prospective brain imaging of participants in PROGRESS should provide a unique opportunity to identify patient characteristics predictive of SBI and to investigate the effect of long-term blood pressure lowering with an ACE inhibitor based regimen on the progression of SBI.
Methods
The PROGRESS CT Substudy was conducted by 33 collaborating hospitals as a formal substudy of the PROGRESS trial. All patients enrolled in the Japanese arm of PROGRESS were considered for participation in this substudy. The protocol of the PROGRESS CT Substudy, including the eligibility criteria and the methods of recruitment, randomization, follow-up, and clinical assessment, were the same as those for PROGRESS, except the addition of annual CT scanning. Details of the design and methods of PROGRESS have been published elsewhere (26, 27) .
Study Population
Patients who were potentially eligible for enrolment in the PROGRESS trial had a history of transient ischemic attack (TIA) or stroke within the past 5 years, while patients with subarachnoid hemorrhage were excluded. Both normotensive and hypertensive patients were eligible for inclusion. Patients already on antihypertensive therapy were eligible if they were not taking an ACE inhibitor and had neither a clear indication for, nor a definite contraindication to, such treatment. Eligible patients were aged 30 years or older, were well enough to attend the participating clinics as outpatients, and were able to give informed consent. After a 4-week run-in period for the confirmation of patient's tolerance and compliance, enrollment in the Japanese arm of PROGRESS was performed. Patients were randomly assigned to receive perindopril (4 mg daily) with or without the diuretic indapamide (2 mg daily) or matching placebo(s). Physicians were given the option to choose between monotherapy (perindopril alone) or combination therapy (perindopril plus indapamide), because of uncertainty among the collaborating doctors about the safety of intensive bloodpressure-lowering for patients with a previous stroke or TIA. Treatment allocation was stratified by sex, age (in decades), initial systolic blood pressure (in 20-mmHg strata), the use of combination therapy (perindopril with indapamide or identical placebos) or monotherapy (perindopril alone or identical placebo) and the initial diagnosis (TIA, ischemic stroke, hemorrhagic stroke, or unknown type of stroke). In order to be eligible for the PROGRESS CT Substudy, a baseline CT scan had to be performed within 6 months before randomization or within 30 days after randomization. Following randomization, the patients were reviewed after 2 weeks, as well as after 1, 3, 6, 9, and 12 months, and then at 6-months intervals, as described previously (26). At all visits, the blood pressure was measured in the seated position after 5 min of rest with the cuff on the left arm. All measurements were made with a standard mercury sphygmomanometer and two blood pressures were obtained at an interval of 1-2 min. The first and fifth Korotokof sounds were used to indicate the systolic and diastolic pressure, respectively. Then the mean systolic and diastolic blood pressures were calculated from the two measurements and were used for analysis. Brain CT scanning, assessment of cognitive function, and assessment of activities of daily living (ADL) were performed annually. Cognitive function was screened by the Mini-Mental State Examination (MMSE) (28) , and ADL were evaluated by the Barthel and Lindley classification (29, 30) . Brain CT scanning and screening for dementia using the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria were also performed on completion of the study. Follow-up was completed in February 2001.
Definition of Subtypes of Cerebral Infarction
The most recent stroke before randomization was defined as the index stroke and the following criteria were used to categorize the index stroke subtype. Lacunar stroke: cerebral infarction with 1) maintenance of consciousness and higher brain functions as well as 2) one of the typical lacunar syndromes such as pure motor hemiparesis. Cardioembolic stroke: cerebral infarction with 1) no lacunar characteristics, 2) no definite evidence of carotid artery disease in the neck, and 3) existence of a major cardioembolic source (e.g., atrial fibrillation, myocardial infarction within the previous 6 weeks, cardiomyopathy, endocarditis, or a prosthetic heart valve). Large artery infarction: cerebral infarction with 1) no lacunar characteristics, 2) no major cardioembolic source, and 3) evidence of carotid artery disease in the neck (e.g., a bruit or stenosis of more than 50% on a duplex scan). Unclassified cerebral infarction: cerebral infarction that did not fit the lacunar, cardioembolic, or large artery categories.
Brain Imaging and Assessment

Timing
Baseline CT was performed in the period from 6 months before to 30 days after randomization. Follow-up CT scanning was performed annually and on completion of the study, even if the patient suffered a recurrent stroke, provided that attendance at the outpatient clinic was possible. At each time of assessment, CT films were evaluated by the investigators and then submitted to the CT Evaluation Committee. Evaluation of all CT films was completed before unblinding.
Radio Parameters
The slice thickness, the slice angle from the orbito-meatal line, and the other radiographic parameters were those usually employed at each institution. However, it was mandatory to employ the same parameters for each scan done on a single patient.
Assessment of CT Findings
Follow-up CT films were compared with the baseline films to assess the development of new foci, changes in the size of existing lesions, changes in the severity of brain atrophy, and other changes. All CT films were read by 3 members of the CT Evaluation Committee and their consensus interpretation was recorded.
Ischemic Foci
At each assessment, the investigator and the members of the CT Evaluation Committee examined each infarct and determined the following parameters: 1) affected hemisphere (left, right, or both), 2) size (small [<1.5 cm in diameter], medium [between small and large], or large [involving more than half of a hemisphere]), 3) the vessel(s) involved (cortical, perforating, or both), and 4) the vascular territory (anterior cerebral artery [ACA] territory, middle cerebral artery [MCA] territory, posterior cerebral artery [PCA] territory, or vertebrobasilar [VB] territory). The VB territory was further divided into the thalamus and the brain stem/cerebellum. Each infarct was marked on the CT films. For every new lesion that was detected during the follow-up period, the CT Evaluation Committee determined whether or not it was asymptomatic based on reports from the investigators.
Hemorrhagic Foci
At the time of each assessment, the investigator and the members of the CT Evaluation Committee examined each hemorrhagic focus to determine the following parameters: 1) affected hemisphere (left, right, or both), 2) size (small [<1.5 cm in diameter], medium [between small and large], or large [involving more than half of a hemisphere]), and 3) location (cerebrum [putamen, thalamus, or subcortex], cerebellum, or pons). Every hemorrhagic lesion was marked and numbered on the CT films. For every new lesion that was detected during the follow-up period, the CT Evaluation Committee determined whether or not it was asymptomatic based on reports from the investigators.
Brain Atrophy
The members of the CT Evaluation Committee made the following measurements on each baseline CT film and the last follow-up CT film. 1) Frontal horn index (FHI): The maximum width between the anterior horns of the lateral ventricles and the inner cranial diameter along the same line were measured and the ratio of these widths was calculated (31). 2) Cella media index (CMI): The maximum width between the bodies of the two lateral ventricles and the inner cranial diameter along the same line were measured and the ratio of these widths was calculated (31) . FHI and CMI mainly display atrophy of the subcortical structures, and are strongly influenced by the slice level and the shape of the cranial bones. To detect any difference in the progression of brain atrophy between the two groups, the following procedures were done before unblinding. Lines for measurement of the FHI and CMI were drawn on the baseline CT films. To measure these indices on the final follow-up CT films, the CT Evaluation Committee drew lines at the same sites after overlaying the follow-up films on the baseline films. If lines could not be drawn at the same place, the data were not used for analysis. 3) Grading of cortical atrophy: Using standard CT films showing several grades of cortical atrophy as a guide, cortical atrophy was graded as 1) absent, 2) mild, 3) moderate, or 4) severe by consensus among the 3 members of the committee (Fig. 1) . To minimize bias during this sub- 
Other Changes
At each time of assessment, the CT Evaluation Committee also examined CT films to detect the following changes: 1) brain tumors, 2) traumatic brain lesions, 3) subarachnoid hemorrhage, and 4) other lesions. Even if follow-up CT films did not demonstrate a previously documented lesion, new lesions were added to the previous number at follow-up. Because of differences in the CT scanners used by the collaborating hospitals, white matter changes (such as periventricular hyperlucency) were not evaluated.
End-Points
The primary end-point was a composite end-point combining recurrence of symptomatic stroke and detection of new SBI that were not present on baseline CT scans. The secondary end-points were the total number of SBI detected during the follow-up period and the brain atrophy indices.
Statistical Analysis
In all analyses, participants were grouped according to their original randomized treatment allocation and the effects of treatment were analyzed according to the intention-to-treat principle. The χ 2 test and Fisher's exact test were used to compare the number of patients with new SBI stratified by index stroke subtype and the number of patients with new SBI stratified by functional outcome. Because the total number of new SBI could include multiple events per patient, a Poisson regression model was used to compare these differences between groups. Changes of FHI, CMI, and the cortical atrophy index during the study period were analyzed using McNemar's test. We conducted Cox proportional hazards regression analysis to examine the patient characteristics at baseline as the prognostic factor of new SBI. The initial analyses included adjustment for age, sex, and treatment allocation (active/placebo), and hazard ratios and 95% confidence intervals (CIs) were calculated. Subsequently, blood pressure, index stroke subtype (dummy variables for 7 categories of lacunar stroke, large artery infarction cardioembolic stroke, unclassified infarction, TIA/transient monocular blindness (TMB), cerebral hemorrhage and unknown type of stroke), antiplatelet therapy, statin therapy, peripheral arterial disease, coronary artery disease, diabetes mellitus, baseline MMSE score (<25), baseline Barthel index (<100), and number of months from recent stroke were entered into the model to calculate multivariate-adjusted hazard ratios. Differences of blood pressure between the randomized groups during the follow-up period were estimated using linear mixed models. In all analyses, a p value of less than 0.05 was considered significant.
Results
Baseline Characteristics and Follow-Up
A total of 938 potentially eligible participants were registered for the PROGRESS trial in Japan and 815 were randomized to enter the double-blind phase of the trial after a 4-week run-in period. Excluding 87 patients without baseline CT scans and 61 patients who were scanned outside the specified time, 667 patients were enrolled in the PROGRESS CT Substudy, comprising 339 in the placebo group and 328 in the active treatment group (Fig. 2) . Some patients had no baseline CT scans because MRI was used to evaluate their index stroke. The excluded patients had slightly higher systolic blood pressures and greater use of antihypertensive medications at entry.
Among the 667 patients, 546 (82%) had only one stroke or TIA, while the other patients (18%) had multiple such events. The index event was cerebral infarction in 79% of the patients, cerebral hemorrhage in 13%, and TIA or TMB in 8%. The clinical subtype of cerebral infarction was lacunar stroke in 347 patients, large artery infarction in 95 patients, and cardioembolic stroke in 36 patients. Antihypertensive therapy was already being used by 369 of the 667 patients (55%), with calcium channel blockers being the most common drugs (345/667 patients, 52%). A total of 81% of all patients with ischemic cerebrovascular disease (including TIA and TMB) were receiving antiplatelet therapy or anticoagulant therapy. The antiplatelet agent was aspirin in 34%, so other antiplatelet agents were more common (67%). Oral anticoagulants were most commonly used to treat patients with cardioembolic stroke, being administered to 62% of these patients. A total of 126 patients had no detectable lesions on baseline CT scans, while ischemic lesions were detected in 461 patients, hemorrhagic lesions in 49 patients, and both types of lesions in 31 patients. The total number of ischemic foci was 958, most of which were in the MCA ter- Fig. 2 . Disposition of the subjects.
ritory (759/958, 79%). Eighty hemorrhagic foci were observed, with putaminal hemorrhage being the most common type (47/80, 59%). There were no significant differences between the placebo and active treatment groups for any of the recorded clinical characteristics at baseline ( Table 1) .
The average follow-up period was 3.9 years in the placebo group and 3.9 years in the active treatment group. Most of the patients (762/815, 93%) in the Japanese arm of PROGRESS were treated by monotherapy (32) , and the percentage receiving monotherapy in the placebo group and the active treatment group was 94.7% and 91.8%, respectively. Forty four randomized patients had no follow-up CT scans. These patients were slightly older and had slightly lower diastolic blood pressures at baseline.
Blood Pressure
Blood pressure (systolic/diastolic) was reduced by an overall average of 5.0/2.6 mmHg (SEM 0.3/0.2), among those assigned active treatment compared with those assigned placebo (Fig. 3, p<0.0001 ).
Clinical Outcome
There were 88 recurrent strokes with the annual rate of recurrent symptomatic stroke and the detection rate of new SBI on CT scans being 3.6% and 4.5%, respectively. The frequency of the primary end-point was similar in the placebo group (26.5%) and in the active treatment group (25.9%).
Data on asymptomatic foci detected by CT during the post-randomization period are summarized in Table 2 . During the follow-up period, new SBI were detected in 15.0% of the placebo group vs. 12.5% of the active treatment group ( p 0.34). There were 62 new SBI in 51 of the 339 placebo patients and 57 new SBI in 41 of the 328 patients on active treatment, with no statistically significant difference between the two groups ( p 0.75). Among the patients who had a history of large artery infarction, none of those from the active treatment group developed new SBI during follow-up, while 12.5% of patients from the placebo group had new SBI ( p 0.02).
There were no significant differences between the two groups with respect to the decline of cognitive function based on the MMSE score, the frequency of dementia at the 33 (10) 26 (8) Barthel index <100
51 (15) 41 (13) Mean follow-up period (years) 3.9 (1) 4 (1) TIA, transient ischemic attack; TMB, transient monocular blindness; MMSE, mini-mental state examination. Numbers are expressed as mean and SD in parenthesis.
Fig. 3. Changes in systolic and diastolic blood pressure among participants assigned active treatment and those assigned placebo (R randomization). Time scale shows occasions when blood pressure was recorded.
final visit, and the incidence of disability assessed using the Barthel index (Table 2) . At the end of follow-up, cerebral atrophy showed no significant change on the basis of the FHI and CMI data, but there was a increase of patients with moderate or severe cortical atrophy in both groups (Table 3 ). When we divided the patients into four subgroups according to the presence or absence of SBI and a severe cognitive decline (defined as a decrease of the MMSE score by more than 3 points) at the last available visit, the incidence of a severe cognitive decline was similar in patients with new SBI (9/94, 9.6%) and patients without SBI (39/573, 6.8%). The incidence of dementia was also similar in patients with new SBI (2/94, 2.1%) and patients without SBI (14/573, 2.4%).
Age, sex and treatment-adjusted hazard ratios for new SBI are presented in Table 4 . The only significant effect ( p<0.05) was for diastolic blood pressure where the hazard ratio (95% CI) was 1.34 (1.10-1.63) for each additional 10 mmHg of blood pressure. However, there was some indication of an adverse effect (0.05< p <0.1) for an increase in systolic blood pressure, hypertension and a history of lacunar stroke, whilst those with a history of large artery infarction had a similar, marginally non-significant, tendency towards lower risk. Additional adjustment for all the other variables included in this table had no material effect on the hazard ratios except that the hazard ratio for cerebral hemorrhage changed from 1.13 to 0.79 after the additional adjustment. However, the revised value was still within the wide CI for the original estimate as shown in Table 4 .
In this model, we did not include systolic blood pressure, and hypertension (blood pressure ≥ 140/90 mmHg) as a covariate because of the possible colinearity with diastolic blood pressure. The index stroke subtype was included as a categorical variable (dummy variables for 7 categories of lacunar stroke, large artery infarction cardioembolic stroke, unclassified infarction, TIA/TMB, cerebral hemorrhage and unknown type of stroke) and we treated the lacunar stroke as a reference group.
Discussion
Because of the paucity of longitudinal studies involving repeated brain imaging, little is known about the incidence, risk factors, and clinical impact of the occurrence of new SBI. Two early MRI-based studies demonstrated an increase of SBI, mostly small lacunar infarcts, in patients with hypertension (4, 5) . In the present study, we confirmed that the baseline diastolic blood pressure was significantly associated with the risk of SBI. We also confirmed that most SBI were small lacunar-type infarcts. The risk of SBI might be higher in patients with a history of lacunar infarct than in those with a history of other type of stroke. The Veterans Affairs Stroke Prevention in Nonreheumatic Atrial Fibrillation (SPINAF) study, a prospective randomized study to clarify the efficacy of low-dose warfarin, demonstrated that SBI were very infrequent in patients with nonrheumatic atrial fibrillation. By repeated CT scanning, the SPINAF study only detected an annual incidence of 1.01% for SBI in the placebo group and 1.57% in the warfarin group (6) . Thus, the type of index stroke itself might be a risk factor for new SBI. However, we observed no association between the index stroke subtype and the risk of SBI by Cox regression analysis after adjustment of the baseline blood pressure level.
In the present study, we found new SBI in 109 out of 667 patients (16.3%) and significant progression of cortical atrophy in both groups by CT over a mean follow-up period of 3.9 years. Recently, the Rotterdam Scan Study, a prospective population-based cohort study using repeated MRI, demonstrated that 75 out of 648 participants (11.6%) who were free of stroke developed new SBI during a mean follow-up period of 3.6 years (3). Detection of asymptomatic brain lesions by CT scanning is definitely inferior to detection by MRI. According to Lechner, of 155 lesions found by MRI, only 11 were detectable by CT (33) . However, we employed CT rather than MRI because it is more widely available in Japan and it is easier to standardize the data acquisition parameters. The higher incidence of new SBI in our CT-based study than in the MRI-base Rotterdam Scan Study may be attributable to the different characteristics of the study populations. Small lesions deep in the brain may be missed by CT or MRI due to slight differences in the slice angle or slice level. In the present study, lesions that were observed once were not considered to have resolved if they were undetectable at the second or later assessments, so repeated CT scanning may have contributed to an increase in the number of lesions. However, this effect should be small because constant radiographic parameters were employed for each patient. In any case, such an error should have affected both groups equally, (3, 14) or nocturnal blood pressure (14, 15) can increase the risk of SBI and dementia. Qiu et al. found that a low diastolic blood pressure is associated with an increased risk of dementia in a longitudinal community-based observational study (n 1,270) (14) . The association was particularly pronounced in persons who took antihypertensive drugs, so they suggested that a low diastolic blood pressure may increase dementia by affecting cerebral perfusion. However, it remains controversial whether the decline in blood pressure is a consequence of or a cause of brain disease (34) . The PROGRESS Dementia Study has already demonstrated that perindopril-based therapy reduces the risk of dementia and of cognitive decline in patients who suffered recurrent stroke by 34% ( p 0.03) and 45% ( p<0.001) respectively (25) . Moreover, it is noteworthy that annual CT scanning did not reveal a significant increase of SBI in the active treatment group. These results are consistent with the demonstration that cerebral blood flow is well maintained when perindopril is used to lower blood pressure (35, 36) . Although the numbers of patients with various types of stroke in our study were too small to draw reliable conclusions, it is of interest that subgroup analysis suggested a protective effect of perindopril against SBI in the subgroup of patients with a history of large artery infarction, despite the relatively small blood pressure difference observed (Table  2) . Studies on the effects of the ACE inhibitor ramipril on the progression of carotid atherosclerosis have yielded conflicting results. On the one hand, the SECURE study, a substudy of the Heart Outcomes Evaluation (HOPE) Trial, demonstrated that high dose ramipril (10 mg) could slow progression of carotid atherosclerosis using B mode ultrasound (37) . In contrast, the PART 2 study using the same dose of ramipril was unable to detect any benefit (38) . A preventive effect of perindopril on the progression of existing atherosclerotic lesions has been demonstrated in cholesterolfed rabbits (21) and diabetic apolipoprotein E-deficient mice (22) . Thus, recent experimental and clinical evidence suggests that ACE inhibitors may have a protective effect against atherosclerosis, so further studies are required to investigate this possibility.
Although there were 59 patients demonstrating a decline in MMSE score more than 3 points (31 in placebo group and 28 in active group) after the follow-up period, there was no significant increase in the number of patients with MMSE score less than 25 points. It has been suggested by recent epidemiological (34, (39) (40) (41) and clinico-pathologic (42) (43) (44) data that hypertension may be associated with the later development of Alzheimer's disease and vascular dementia. Prevalence of dementia is strongly associated with age. Dementia under 65 years old is rare but the prevalence of dementia significantly increased after 75 years old (45) . Age of the participants in this study, 64 9 years old, may be relatively young for studying dementia. Because PROGRESS was not a trial attempted to identify the optimal blood pressure target, our CT Substudy does not answer the question whether there is an optimal blood pressure level for prevention of SBI. Further studies are necessary to explore the association among blood-pressure-lowering, development of SBI and dementia especially in older patients.
In conclusion, blood pressure-lowering with a perindoprilbased regimen did not increase the risk of SBI and brain atrophy in patients with a history of stroke. Reduction of the diastolic blood pressure may decrease the risk of SBI irrespective of the type of index stroke.
